Oppenheimer raised the firm’s price target on Atai Life Sciences (ATAI) to $16 from $14 and keeps an Outperform rating on the shares as recent dynamics bode well for BPL-003. As large cap players vie for leadership in neuroscience, psychiatry is increasingly in focus while acquisitions of smaller players are an important source of innovation, Oppenheimer notes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Psychedelic: Filament reports compassionate use approval for psilocybin
- ATAI Life Sciences: Strategic Positioning and Diversified Portfolio Drive Buy Rating
- Atai Life Sciences price target raised to $15 from $10 at H.C. Wainwright
- Sarepta upgraded, Tapestry downgraded: Wall Street’s top analyst calls
- Atai Life Sciences initiated with an Outperform at Oppenheimer